Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

European Journal of Cancer

Volumn 68, Issue , 2016, Pages 163-172

  Bouchahda, Mohamed ^a,b,c   Boige, Valérie ^d   Smith, Denis ^e   Karaboué, Abdoulaye ^b,f   Ducreux, Michel ^d   Hebbar, Mohamed ^g   Lepère, Céline ^h   Focan, Christian ⁱ   Guimbaud, Rosine ^j   Innominato, Pasquale ^a,b,m   Awad, Sameh ^a   Carvalho, Carlos ^k   Tumolo, Salvatore ^l   Truant, Stephanie ^g   De Baere, Thierry ^d   Castaing, Denis ^a   Rougier, Philippe ^h   Morère, Jean François ^a   Taieb, Julien ^h   Adam, René ^a,b   Lévi, Francis ^a,b,m   more..

^a HÔPITAL PAUL BROUSSE   (France)

^b Centre National de la Recherche Scientifique   (France)

^c Ramsay GDS Clinique du Mousseau   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

^f Research and Therapeutic Innovation   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ Clinique Saint Joseph   (Belgium)

^j TOULOUSE UNIVERSITY HOSPITAL   (France)

^k HOSPITAL FERNANDO FONSECA   (Portugal)

^l Santa Maria Degli Angeli Community Hospital   (Italy)

^m UNIVERSITY OF WARWICK   (United Kingdom)

more..

Author keywords

Colorectal cancer; Early tumour response; Hepatic artery infusion; Liver metastases; Triplet chemotherapy

Indexed keywords

CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL PREDICTION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; WILD TYPE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; FATIGUE; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84992154362     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.09.011     Document Type: Article

References (29)

1. [1] Heinemann, V., von Weikersthal, L.F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.E., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:10 (2014), 1065–1075.
2. [2] Cheng, Y.D., Yang, H., Chen, G.Q., Zhang, Z.C., Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 7 (2013), 1315–1322.
3. [3] Van Cutsem, E., Köhne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:14 (2009), 1408–1417.
4. [4] Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., de Braud, F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:5 (2009), 663–671.
5. [5] Sobrero, A.F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y.A., Lutz, M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:14 (2008), 2311–2319.
6. [6] Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:4 (2004), 337–345.
7. [7] Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:20 (2007), 2040–2048.
8. [8] Adam, R., Wicherts, D.A., de Haas, R.J., Ciacio, O., Lévi, F., Paule, B., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 27:11 (2009), 1829–1835.
9. [9] Chiappa, A., Makuuchi, M., Lygidakis, N.J., Zbar, A.P., Chong, G., Bertani, E., et al. The management of colorectal liver metastases: expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol 72:1 (2009), 65–75.
10. [10] Ksienski, D., Woods, R., Speers, C., Kennecke, H., Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol 17:12 (2010), 3085–3093.
11. [11] Ye, L.C., Wei, Y., Zhu, D.X., Chen, T., Xu, J., Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. J Gastroenterol Hepatol 30:4 (2015), 674–679.
12. [12] Douillard, J.Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J.H., Tabernero, J., Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 51:10 (2015), 1231–1242.
13. [13] Piessevaux, H., Buyse, M., Schlichting, M., Van Cutsem, E., Bokemeyer, C., Heeger, S., et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31:30 (2013), 3764–3775.
14. [14] Cremolini, C., Loupakis, F., Antoniotti, C., Lonardi, S., Masi, G., Salvatore, L., et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26:6 (2015), 1188–1194.
15. [15] Tang, P.A., Bentzen, S.M., Chen, E.X., Siu, L.L., Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:29 (2007), 4562–4568.
16. [16] Buyse, M., Thirion, P., Carlson, R.W., Burzykowski, T., Molenberghs, G., Piedbois, P., Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356:9227 (2000), 373–378.
17. [17] Lévi, F.A., Boige, V., Hebbar, M., Smith, D., Lepère, C., Focan, C., et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 27:2 (2016), 267–274.
18. [18] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., et al. New guidelines to evaluate the response to treatment in solid tumors. Special article. J Natl Cancer Inst 92 (2000), 205–216.
19. [19] Cohen, A.D., Kemeny, N.E., An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8:6 (2003), 553–566.
20. [20] Bouchahda, M., Lévi, F., Adam, R., Rougier, P., Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer 47:18 (2011), 2681–2690.
21. [21] Bouchahda, M., Adam, R., Giacchetti, S., Castaing, D., Brezault-Bonnet, C., Hauteville, D., et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 115:21 (2009), 4990–4999.
22. [22] Zhao, B., Lee, S.M., Lee, H.J., Tan, Y., Qi, J., Persigehl, T., et al. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm. Clin Cancer Res 20:13 (2014), 3560–3568.
23. [23] Monteil, J., Mahmoudi, N., Leobon, S., Roudaut, P.Y., El Badaoui, A., Verbeke, S., et al. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans. Anticancer Res 29:7 (2009), 2563–2568.
24. [24] Modest, D.P., Laubender, R.P., Stintzing, S., Giessen, C., Schulz, C., Haas, M., et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol 52:5 (2013), 956–962.
25. [25] Giessen, C., Laubender, R.P., Fischer von Weikersthal, L., Schalhorn, A., Modest, D.P., Stintzing, S., et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 104:6 (2013), 718–724.
26. [26] Kogawa, T., Doi, A., Shimokawa, M., Fouad, T.M., Osuga, T., Tamura, F., et al. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Target Oncol 10:1 (2015), 125–133.
27. [27] Heinemann, V., Stintzing, S., Modest, D.P., Giessen-Jung, C., Michl, M., Mansmann, U.R., Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 51:14 (2015), 1927–1936.
28. [28] Petrelli, F., Pietrantonio, F., Cremolini, C., Di Bartolomeo, M., Coinu, A., Lonati, V., et al. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. Eur J Cancer 51:7 (2015), 800–807.
29. [29] Huff, C.A., Matsui, W., Smith, B.D., Jones, R.J., The paradox of response and survival in cancer therapeutics. Blood 107:2 (2006), 431–434.